false 0001177648 0001177648 2021-05-06 2021-05-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2021

 

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35839

04-3205099

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

500 Arsenal Street,

Watertown, Massachusetts

 

02472

(Address of principal executive offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

ENTA

 

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 


 

 

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2021, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended March 31, 2021. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

 

Description

 

 

 

99.1

 

Press Release of Enanta Pharmaceuticals, Inc. dated May 6, 2021, reporting Enanta’s financial results for the fiscal quarter ended March 31, 2021

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

1


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ENANTA PHARMACEUTICALS, INC.

 

 

 

 

Date: May 6, 2021

 

By:

/s/ Paul J. Mellett

 

 

 

Paul J. Mellett

 

 

 

Senior Vice President, Finance and Administration and Chief Financial Officer

 

2

Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Enanta Pharmaceuticals Charts.
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Enanta Pharmaceuticals Charts.